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Abstract
Background: MUC7 12-mer (RKSYKCLHKRCR), a cationic antimicrobial peptide derived from
the human low-molecular-weight salivary mucin MUC7, possesses potent antimicrobial activity in
vitro. In order to evaluate the potential therapeutic application of the MUC7 12-mer, we examined
the effects of mono- and divalent cations, EDTA, pH, and temperature on its antimicrobial activity.
Methods:  Minimal Inhibitory Concentrations (MICs) were determined using a liquid growth
inhibition assay in 96-well microtiter plates. MUC7 12-mer was added at concentrations of 1.56–50
μM. MICs were determined at three endpoints: MIC-0, MIC-1, and MIC-2 (the lowest drug
concentration showing 10%, 25% and 50% of growth, respectively). To examine the effect of salts
or EDTA, a checkerboard microdilution technique was used. Fractional inhibitory concentration
index (FICi) was calculated on the basis of MIC-0. The viability of microbial cells treated with MUC7
12-mer in the presence of sodium or potassium was also determined by killing assay or flow
cytometry.
Results: The MICs of MUC7 12-mer against organisms tested ranged from 6.25–50 μM. For C.
albicans, antagonism (FICi 4.5) was observed for the combination of MUC7 12-mer and calcium;
however, there was synergism (FICi 0.22) between MUC7 12-mer and EDTA, and the synergism
was retained in the presence of calcium at its physiological concentration (1–2 mM). No antagonism
but additivity or indifference (FICi 0.55–2.5) was observed for the combination of MUC7 12-mer
and each K+, Na+, Mg2+, or Zn2+. MUC7 12-mer peptide (at 25 μM) also exerted killing activity in
the presence of NaCl, (up to 25 mM for C. albicans and up to 150 mM for E. coli, a physiological
concentration of sodium in the oral cavity and serum, respectively) and retained candidacidal
activity in the presence of KCl (up to 40 mM). The peptide exhibited higher inhibitory activity
against C. albicans at pH 7, 8, and 9 than at pH 5 and 6, and temperature up to 60°C did not affect
the activity.
Conclusion: MUC7 12-mer peptide is effective anticandidal agent at physiological concentrations
of variety of ions in the oral cavity. These results suggest that, especially in combination with EDTA,
it could potentially be applied as an alternative therapeutic agent for the treatment of human oral
candidiasis.
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Background
Cationic antimicrobial peptides (CAMPs) are one of the
body's host defenses against invading microorganisms.
These peptides have broad-spectrum antimicrobial activ-
ity, including antibacterial, antiviral, and antifungal activ-
ity. They have a rapid onset of killing, cidal activity, and
concomitant broad anti-inflammatory activities [1].
CAMPs show little or no toxicity towards mammalian
cells, and have a low tendency to elicit resistance, and
have thus become a promising novel group of antibiotics
[2].
MUC7 peptides are the CAMPs derived from the human
low molecular weight salivary mucin MUC7, a compo-
nent of innate immunity (the first-line of the host defense
system against pathogens). MUC7, the low molecular
weight human salivary mucin glycoprotein (357 aa resi-
dues), protects the oral cavity from microbial infections
through more general protective mechanisms rather than
the direct killing of microorganisms. The peptides derived
from the N-terminal region of MUC7 have a significant
fungicidal activity in vitro [3-6]. The representative MUC7
peptide, MUC7 12-mer (RKSYKCLHKRCR), a cationic
peptide spanning residues 40–51 of the MUC7, possesses
potent antimicrobial activity in low-ionic-strength buffers
and in low salt RPMI 1640 medium. This peptide exhibits
synergistic antifungal effects with histatin 5 12-mer (Hsn5
12-mer) and with miconazole [7].
In effort to establish a transition from in vitro activity of
MUC7 12-mer into clinical efficacy, it is necessary to
investigate the factors affecting antimicrobial activity of
MUC7 peptides. Our previous study showed that the pep-
tides face the challenge of the degradation by proteases in
saliva. We have demonstrated that antifungal activity of
MUC7 12-mer-L in human whole saliva was enhanced in
the presence of protease inhibitors and EDTA, and MUC7
12-mer-D isomer exerted higher antifungal activity com-
pared to MUC7 12-mer-L in human whole saliva [8].
Beside proteases, salt sensitivity of antimicrobial peptides
poses a major obstacle in their development as novel anti-
biotics. In addition, other factors such as pH value and
temperature may also affect the antimicrobial activity of
the peptides.
In this study we examined the effects of monovalent (Na+
and K+) and divalent (Ca2+, Mg2+, and Zn2+) cations,
EDTA (a chelator of divalent cations), pH, and tempera-
ture on the antimicrobial activity of the MUC7-12-mer,
with a special emphasis on the activity against C. albicans.
Methods
Peptides and chemicals
MUC7 12-mer (RKSYKCLHKRCR, amino acids 40–51 of
the parent human salivary mucin, MUC7) and Hsn5 12-
mer (AKRHHGYKRKFH, amino acids 4–15 of the parent
human salivary histatin 5) were custom-synthesized by
Bio-Synthesis (Lewisville, Texas). The company analyzed
the prepared peptide by high-performance liquid chroma-
tography and mass spectrometry. The purity (>70%) was
taken into consideration in preparing the stock solution
of each peptide for antifungal assays. The peptide was dis-
solved in sterile de-mineralized water at 10 mg/mL; aliq-
uots were freeze-dried and stored at -20°C. For each
experiment, the freeze-dried peptides were re-dissolved at
1 mg/mL in sterile dd-water. The stock solutions of 1 M
each EDTA, NaCl, KCl, CaCl2, MgCl2, and Zn2 SO4 were
prepared in de-mineralized water. The working solutions
were obtained by diluting the stock and filter-sterilization.
Microbial strains and growth media
C. albicans DIS (clinical isolate from denture induced sto-
matitis), Escherichia coli HB101 and Streptococcus mutans
UA159 were stock strains from our lab. The strains were
stored at -80°C in glycerol. For each experiment, C. albi-
cans cells were cultured freshly from frozen stock on Sab-
ouraud dextrose agar (SDA, Difco) for 24 hours at 37°C.
To prepare fungal cell suspension for antifungal activity
assays, colonies were picked from the plate and resus-
pended in 10 mM sodium phosphate buffer (pH 7.4) for
killing assay, and in 12.5% Sabouraud dextrose broth
(SDB) for MIC assay. A 25% brain heart infusion (BHI)
was used for bacterial susceptibility test (MIC test). To pre-
pare E. coli cell suspension for killing assays, the overnight
culture was harvested by centrifugation (3783 × g, 10
min), washed once with 10 mM sodium phosphate-buff-
ered saline (PBS, pH 7.2) and resuspended in PBS. The
concentrations of the microbial cells were adjusted to 1 ×
105 cells/mL.
MIC susceptibility tests
The effect of salt concentration on the antimicrobial activ-
ity of the peptides was tested by determining the MICs of
the peptides at various cation concentrations. MICs of
MUC7 12-mer were determined by the microdilution
method as described previously with some modifications
[7]. Briefly, two-fold serial dilutions of test agents were
prepared, with 12.5% SDB at a volume of 200 μl per well,
in 96-well flat-bottom microtiter plates (Costar, Cam-
bridge, MA). The final concentration of the antifungal
agents ranged from 3.13 to 50 μM for MUC7 12-mer, and
2.5 to 160 μM for cations or EDTA. The microtiter plate
was inoculated with cell suspension (final concentration
1 × 104 cells per mL) and incubated at 37°C for 48 h.
Afterwards, the absorbance was measured at 595 nm by
using a microplate reader (Model AD 340, Beckman Coul-
ter) to assess the cell growth. Minimal inhibitory concen-
trations (MIC) were determined at three endpoints: MIC-
0, MIC-1 and MIC-2, indicating the lowest agent concen-
tration showing no more than 10%, 25% and 50% growthAnnals of Clinical Microbiology and Antimicrobials 2007, 6:14 http://www.ann-clinmicrob.com/content/6/1/14
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respectively, in comparison to that of the agent-free con-
trol. For each set of conditions, the MIC tests were carried
out independently two or three times, using duplicate
samples each time. The MICs were reported as the geomet-
ric means and the 95% confidence intervals for the means.
The effect of pH on the antimicrobial activity of MUC7
12-mer was tested by determining the MIC of the peptide
at a variety of pH values. This was achieved by altering the
pH of the media with 5 M HCl or NaOH. The peptide was
tested in pH conditions from pH 5 to pH 9.
The effect of temperature on the antimicrobial activity of
MUC7 12-mer was tested by determining the MICs of the
peptides after incubation at temperatures 60 and 90°C for
30 min followed by cooling to room temperature.
Synergy tests
Checkerboard titrations were used to test the interaction
of MUC7 12-mer peptide separately with each divalent
cation, EDTA, and EDTA in the presence of divalent cati-
ons. The tests were performed in 96-well microtiter plates.
A two-dimensional checkerboard (8 × 8) microdilution
technique was selected to span from synergy to antago-
nism.
The assay were performed in the 96-well microtiter plate
in total volume of 200 μl per well. In one dimension, a
two-fold serial dilution of CaCl2, MgCl2, or Zn2 SO4 in
sterile water was prepared across the rows, giving the final
concentrations from 2.5 to 160 μM for divalent cations
and EDTA, and 1–125 mM for monovalent cations. In the
second dimension, a two-fold dilution series of MUC7
12-mer was prepared down the columns, giving a final
concentration from 0.78 to 100 μM. Each well of the
microtiter plate was inoculated with C. albicans DIS cells
suspended in 25% SDB (2 × 12.5%) to a final cell concen-
tration of 1 × 104 cells per mL. For bacteria, S. mutans or E.
coli cells were suspended in 50% BHI (2 × 25%) to a final
cell concentration of 1 × 105 cells per mL. After incubation
at 37°C for 48 h, the absorbance of the culture was meas-
ured at 595 nm by using a microplate reader. MIC was
determined at endpoint MIC-0 and the values were used
for calculating the fractional inhibitory concentration
(FIC), defined as the ratio of the MIC of a drug used in
combination to the MIC of the drug tested alone.
Synergy tests interpretation
The FIC index (FICI, the sum of the FICs) was calculated
as described by Meletiadis et al. 2005 [9]. Briefly, for each
checkerboard assay there were several ΣFICs, ranging from
the  ΣFICmin (the lowest ΣFIC) to ΣFICmax (the highest
ΣFIC). The reported FIC index (FICi) was the ΣFICmin
when the ΣFICmax was lower than 4; when ΣFICmax was
higher than 4, the ΣFICmax was reported as FICi. The ΣFIC-
max was also reported as the FIC index for data sets where
the ΣFICmax was lower than 4 but the ΣFICmin was higher
than 1. If for a data set the ΣFICmin was lower than 0.5 and
the ΣFICmax was higher than 4, both ΣFIC were reported.
The off-scale MIC was converted to the next highest or
lowest two fold concentration. The data represents three
independent experiments. As the FICi are not normally
distributed, the median and the range of FICi among the
replicates were calculated. FICi values = 0.5 have been
considered to indicate synergism; 0.5–1.0, additivity; 1–4,
indifference; and > 4, antagonism.
Killing assay
The assays were performed in a final volume of 40 μl.
Two-fold serial dilutions of NaCl (final concentrations
ranging from 6.25 to 150 mM) and MUC7 12-mer or
Hsn5 12-mer (at a final concentration of 25 μM in each
reaction) were prepared in 10 mM sodium phosphate
buffer (PB), pH 7.4, in a volume of 20 μl. An equal vol-
ume (20 μl) of C. albicans DIS or E. coli HB101 suspended
in the same buffer was then added (to a final concentra-
tion of 5 × 104 cells/ml). After incubation at 37°C for 1.5
hours, the samples were diluted 20-fold with the same
buffer and 50 μl aliquots (approximately 120 cells) of
each sample were plated on tryptic soy agar for E. coli and
SDA for C. albicans. The plates were incubated at 37°C for
24 h aerobically. The number of colony-forming units
(CFUs) was counted. Loss of cell viability (percentage of
killing compared to agent free control) was calculated as
(1- amount of viable cells in the test group)/(amount of
viable cells in the control group) × 100.
Flow cytometric assay
Flow cytometric assays were based on detection of
increased permeability of fungal cells to propidium iodide
(PI), a membrane impermeant DNA-intercalating dye,
following treatment with MUC7 12-mer peptide in the
presence of KCl. Analyses were performed on a Becton
Dickinson FACScalibur system equipped with an argon-
cooled argon laser (488 nm, 5 mW) and standard system
configuration for orange-filtered light detection (620 nm)
using CELLQuest software (Becton Dickinson, Heidel-
berg, Germany). For these analyses, two-fold serial dilu-
tions of KCl ranged from 5 to 80 mM were prepared in 10
mM sodium phosphate buffer (Na-PB), pH 7.4, contain-
ing 2% glucose (PBG). MUC7 12-mer was added to each
tube, giving a final concentration of 25 μM in (0.2 mL). C.
albicans cells subcultured on SDA were suspended in PBG
to give 3 × 106 cells/mL, and aliquots (0.1 mL) of the fun-
gal suspension were then added to the solution contain-
ing the peptide and KCl. After incubation at 37°C for 1.5
h, a 1 mM-filtered solution of PI (Sigma-Aldrich) was then
added to the peptide-treated fungi at a final concentration
of 3 mg/L. The cell suspension without K+ and peptide was
used as the agent free control. The samples were analyzedAnnals of Clinical Microbiology and Antimicrobials 2007, 6:14 http://www.ann-clinmicrob.com/content/6/1/14
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after 4 min of incubation at 37°C. The cell scattergram
and the intensity of fluorescence at FL3 (red fluorescence,
620 nm) were recorded by using a logarithmic scale. The
results are expressed as the percentage of positive cells
showing high fluorescence at FL3. To obtain a positive
control for permeabilization, fungal suspensions were
pelleted and resuspended in cold absolute ethanol for 30
min at -20°C. Ethanol was removed by aspiration follow-
ing centrifugation at 1000 g for 10 min, and the pellet
resuspended in PBG solution. Data analysis was per-
formed with the FCS Express version 3 (De Nova Soft-
ware, Thornhill, Ontario, Canada).
Results
Growth inhibitory activity by MUC7 12-mer in the 
presence of salts or EDTA
The effect of salts or EDTA on the antimicrobial activity of
MUC7 12-mer was examined by determining the FICi val-
ues of each combination pair in the checkerboard. As
shown in Table 1 for C. albicans, the MICs of MUC7 12-
mer were from 6.25 to 50 μM; when combined with the
other test agent, the MICs either increased or decreased.
The MICs of MUC7 12-mer increased 4 fold when com-
bined with Ca2+. After analysis of the data with FIC index
model, FICi value of 4.5 was obtained, indicating antago-
nisms between MUC7 12-mer and Ca2+. In contrast, the
MICs of MUC7 12-mer decreased 8 fold when combined
with EDTA; FICi of 0.22 was obtained in this case, indicat-
ing a synergism between MUC7 12-mer and EDTA. In
addition, Na+, Mg2+, and Zn2+  decreased the MIC of
MUC7 12-mer by 2 fold, while K+ increased the MIC by 2
fold. However, instead of antagonism, an additivity or
indifference (FICi 0.55 to 2.5) was observed in the combi-
nation of MUC7 12-mer and each K+, Na+, Mg2+, or Zn2+.
Interestingly, for growth inhibition of S. mutans and E. coli
(data not shown), synergism (FICi 0.38) between MUC7
12-mer and EDTA, or additivity (0.56) between MUC7
12-mer and Zn2+ was also observed. Instead of antago-
nism, the combination of MUC7 12-mer and Ca2+ exhib-
ited indifference (FICi 2.5) for the inhibition of S. mutans
growth.
The physiological concentration of Ca2+ in human whole
saliva is 1–2 mM [10]. Ca+2 may be the main inhibitory
factor on the activity of MUC7 12-mer in vivo. In fact, as
shown in Table 2, MIC of MUC7 12-mer against C. albi-
cans increased from 18 to 200 μM as the concentration of
Ca2+ increased. Therefore, the effect of EDTA on the anti-
candidal activity of MUC7 12-mer in the presence of Ca2+
was also determined. As pointed out above, the combina-
tion of MUC7 12-mer and EDTA exhibited a synergistic
effect on the anticandidal activity. In the presence of Ca+2
and EDTA (Table 2), MUC7 12-mer still showed strong
activity, with the MIC decrease from 4 to 16 fold com-
pared to the MICs in the presence of Ca+2 without the
Table 1: Interaction of MUC7 12-mer in the combination with salts or EDTA against C. albicans
MIC (μM)a
Combination pairs alone combined FICb FICic
MUC7 12-mer 50 25 0.5
Na+ >250 31 0.062 0.562 (ADD)d
MUC7 12-mer 50 100 2
K+ >250 250 0.5 2.5 (IND)
MUC7 12-mer 12.50 50.00 4.00
Ca2+ >160 80.00 0.50 4.50 (ANT)
MUC7 12-mer 12.50 25.00 1.00
Mg2+ >160 80.00 0.25 1.25 (IND)
MUC7 12-mer 6.25 3.13 0.50
Zn2+ 160.00 7.50 0.05 0.55 (ADD)
MUC7 12-mer 18.75 2.35 0.13
EDTA 75.00 6.25 0.09 0.22 (SYN)
a Minimal inhibitory concentrations (MIC) was determined at the endpoint of MIC-0, which is defined as the lowest agent concentration showing no 
more than 10% growth in comparison to that of the growth control. The data represents the median obtained from three independent 
experiments.
b FIC is a fraction inhibitory concentration that was calculated by dividing the MIC value of agent in combination by the MIC value of the agent alone.
c FICi is a FIC index, indicating the sum of the FICs of the two agents in the pairs.
d Interactions: SYN, synergism (FICi <0.5); ADD, additivity (FICi 0.5–1.0); IND, indifference (FICi 1.0 – 4.0); ANT, antagonism (FICi >4).Annals of Clinical Microbiology and Antimicrobials 2007, 6:14 http://www.ann-clinmicrob.com/content/6/1/14
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EDTA. Synergism was still observed with FICi 0.22 to
0.31.
Killing activity of MUC7 12-mer peptide in the presence of 
sodium and potassium
The effect of peptides on cell viability of C. albicans in the
presence of NaCl is shown in Figure 1. MUC7 12-mer
exhibits 100% killing activity in the presence of NaCl up
to 25 mM, a physiological concentration of Na+ in human
saliva. Some decrease in the activity of the MUC7 12-mer
was observed in the presence of 50 mM NaCl or higher.
However, MUC7 12-mer still exhibited more resistance to
NaCl than Hsn5 12-mer. In the presence of 50 mM NaCl,
MUC7 retained 90% killing activity, while Hsn5 12-mer
40%. Additionally, MUC7 12-mer peptide was effective
against E. coli in the presence of NaCl up to 150 mM (data
not shown), a physiological concentration of Na+  in
plasma.
Figures 2 and 3 show the effect of K+ on the anticandidal
activity of MUC7 12-mer, which was determined with
flow cytometry. Untreated cells stained with PI showed a
very low intensity of fluorescence, expressed as negative
(viable cells, Figure 2a) for PI. In contrast, MUC7 12-mer
or ethanol (data not show) treated cells showed a high red
fluorescence, expressed as positive (dead cells, Figure 2b)
for PI. Candida cells treated with MUC7 12-mer in the
presence of 40 mM KCl still showed PI fluorescence (Fig-
ure 2c) with 96% PI positive cells (Figure 3), although the
PI positive cells deceased to 47% in the presence of 80
mM KCl (Figure 2d and Figure 3). Similarly, when treated
with a low concentration of MUC7 12-mer (5 μM), more
than 96% of Candida cells were killed in the presence of
KCl at concentrations up to 20 mM, and 56% of cells were
killed at 40 mM KCl.
Table 2: Interaction of MUC7 12-mer in the combination with EDTA against C. albicans in the presence of Ca 2+
MIC (μM)
Ca 2+ (mM) Pair alone combined FIC FICi
0 MUC7 12-mer 18.75 2.35 0.13
EDTA 75.00 6.25 0.09 0.22
0.01 MUC7 12-mer 25 6.25 0.25
EDTA 50 3.13 0.0626 0.3126
1 MUC7 12-mer 100 6.25 0.0625
EDTA 100 25 0.25 0.3125
2 MUC7 12-mer 200 6.25 0.03125
EDTA 200 50 0.25 0.28125
All parameters (MIC, FIC, FICi) are defined in table 1 footnote.
Effect of sodium chloride on candidacidal activity of MUC7  12-mer and Hsn5 12-mer, determined by killing assay Figure 1
Effect of sodium chloride on candidacidal activity of 
MUC7 12-mer and Hsn5 12-mer, determined by kill-
ing assay. MUC7 12-mer (blue column) or Hsn5 12-mer 
(red column) (at a final concentration of 25 μM) were incu-
bated with C. albicans (105 cells/ml) in 10 mM Na-PB contain-
ing NaCl (6.25–150 mM). The killing activities were 
determined by viable counting on SDA, comparing the 
number of colonies at each salt concentration to those of the 
agent-free control. Data represents two independent experi-
ments, each performed in duplicate.
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Effect of pH
The effect of pH on the activity of the peptide was estab-
lished by determining the MIC of MUC7 12-mer against
C. albicans DIS at pH values varying from 5 to 9 (Figure 4).
There are no significant differences among the MIC-0,
MIC-1, and MIC-2 (95% confidence intervals overlap).
However, MICs of MUC7 12-mer were higher in acidic
conditions than in neutral and basic conditions, and its
antimicrobial activity was optimum at pH 8 (95% confi-
dence intervals do not overlap).
Effect of temperature
The effect of temperature on the activity of MUC7 12-mer
was determined by heating MUC7 12-mer for 30 min
prior to determining the MIC values (Figure 5). MIC val-
ues of MUC7 12-mer did not significantly change after the
peptide was pre-treated at 60°C; when pre-heated at
90°C, the peptide was still active although its MIC values
slightly increased (MIC-0 = 25 μM, one dilution level).
Temperature up to 60°C does not affect the activity of the
peptide.
Discussion
To have a therapeutic use against oral or systemic infec-
tions, antimicrobial peptides need to retain their activity
in physiological conditions. Some antimicrobial peptides
have a broad activity against fungi, bacteria and viruses.
However, a major obstacle in their development as novel
antibiotics is the antagonism between the peptides and
ionic strength in their environment. As a result, the prac-
tical therapeutic use of antibiotic peptides is significantly
impaired or attenuated. Many cationic antimicrobial pep-
tides including β-defensins and the α-defensin HD-5 [11-
16], lactoferricin B [17], histain 5 [18-20], human catheli-
Antimicrobial activity of MUC7 12-mer against C. albicans in the presence of potassium, monitored by flow cytometry Figure 2
Antimicrobial activity of MUC7 12-mer against C. albicans in the presence of potassium, monitored by flow 
cytometry. Fluorescence distribution of the control (untreated) C. albicans cells (a); cells incubated for 90 min at 37°C with 
25 μM MUC7 12-mer (b-d), in the absence of KCl (b), in the presence of 40 mM KCl (c), in the presence of 80 mM KCl (d). 
The cells were stained with propidium iodide (3 μg/mL). Susceptibility to MUC7 12-mer is shown as percentage of C. albicans 
with increasing fluorescence; 10,000 events were analyzed.
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cidin LL-37 [21], protegrins [22], and pleurocidin [23] are
salt sensitive and reduce or lose their antimicrobial activ-
ity at elevated concentrations of mono- or divalent cati-
ons. The persistence of P. aeruginosa infections in the
lungs of patients with cystic fibrosis is attributed to the
susceptibility of epithelial antimicrobial peptides to salt
antagonism [14]. The antibacterial effectiveness of lactof-
erricin B was reduced in the presence of Na+, K+, Mg2+ or
Ca2+ ions, or in the presence of various buffer salts [17].
Hypertonic salt concentrations and heat-inactivated
serum were found to be inhibitory to the bactericidal
activity of Protegrin (PG-1), a broad spectrum antibiotic
peptide isolated from porcine leukocytes [22]. Human
beta-defensin-2 and cathelicidin LL-37 inhibit the growth
of  P. aeruginosa in vitro, but this activity is markedly
reduced in the presence of tears [24]. In saliva, Histatin 5,
a human basic salivary peptide with strong fungicidal
properties in vitro, is salt sensitive and exerts low activity at
high salt conditions [25]. The activity resumed after
removing the salts by dialysis [19].
Saliva is vitally important for the normal functioning of
healthy human beings. Saliva is hypotonic in relation to
serum; the average concentration of Na in saliva is 6–26
mM, versus 140 mM in plasma. Ca2+ and K+ are the major
salivary complex-forming ions [26]. The normal values of
major cations and pH in mixed human saliva and plasma
is summarized in Table 3. Since NaCl is the most predom-
inant salt in vivo, the ability to resist this salt is significant
for antimicrobial peptides to function under physiologi-
Effect of pH on MIC of MUC7 12-mer against C. albicans Figure 4
Effect of pH on MIC of MUC7 12-mer against C. albi-
cans. MIC-0, MIC-1 and MIC-2 indicate the lowest agent 
concentration showing no more than 10%, 25% and 50% 
growth respectively, in comparison to that of the agent-free 
control. The bars indicate the geometric means of two inde-
pendent experiments, each performed in duplicate. The 
error bars show the 95% confidence intervals for the means.
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Effect of potassium on anticandidal activity of MUC7 12-mer Figure 3
Effect of potassium on anticandidal activity of MUC7 
12-mer. C. abicans DIS (106 cells/ml) was treated with 5 and 
25 μM MUC7 12-mer in Na-PB containing KCl (5 – 80 mM) 
and PI fluorescence was analyzed by flow cytometry as 
described in Materials and Methods.
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The effect of temperature on MIC of MUC7 12-mer 
against C. albicans. MUC7 12-mer was heated for 30 min 
prior to determining the MIC values. RT: Room temperature. 
The bars indicate the geometric means of two independent 
experiments, each performed in duplicate. The error bars 
represent the 95% confidence intervals for the means.
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cal conditions. Oral candidiasis is a superficial mucosal
infection caused by C. albicans that is frequently associ-
ated with chemotherapy, organ transplantation, immun-
odeficiency virus infections, underlying disease states or
medications that reduce salivary flow. A NaCl concentra-
tion of 6–26 mM has been reported to be present in the
environment of the epithelial cells of the oral cavity
(Table 3). In this study, the antagonism in terms of growth
inhibition between Na+  and MUC7 12-mer was not
observed by the checkerboard test (Table 1). More impor-
tantly, MUC7 12-mer still exhibited anticandidal activity
at the human salivary Na+ concentration (less than 26
mM; Figure 1). This suggests that MUC7 12-mer peptide is
active for oral candidiasis in oral physiological condi-
tions. This is consistent with the observation of our previ-
ous study using mouse model of oral candidiasis in vivo
[27]. The other reported NaCl-resistant peptides include
clavanins (histidine-rich, amidated alpha-helical antimi-
crobial peptides) [28], CP26, CP29, CEME, CEMA (the
analogues based on the insect cecropin-bee melittin
hybrid peptide) [29], P18 (KWKLFKKIPKFLHLAKKF, an
alpha-helical antimicrobial peptide) [30], cathelicidin
CAP18, SMAP29 [31], and modified forms of LL-37, such
as pentamide-37 [32]. Ponti et al. reported that the cyclic
and linear analogues of esculentin-1, an antimicrobial
peptide from amphibian skin, have a strong killing activ-
ity against gram-negative bacteria, and the activity is not
affected by salts [33].
Nuding, et al. reported that the antibacterial effect of the
isolated cationic extracts from human intestinal biopsies
was diminished towards E. coli with 150 mM NaCl [34].
Our study (data not shown) demonstrated that MUC7 12-
mer exerted strong activity towards E. coli HB101 up to
150 mM NaCl. This suggests a potential for MUC7 12-mer
as a chemotherapeutic agent for the systematic infection
with E. coli without being affected at physiological salt
concentrations.
KCl is one of the salts affecting the antimicrobial activity.
However, to our knowledge, the reported information
regarding the effect of KCl on the antimicrobial peptide
activity is limited. KC is not a principal salt in plasma, but
is predominant in saliva (14–32 mM) [26]. Thus, the role
of KCl should not be neglected for the anticandidial activ-
ity of peptides. Previously, it has been observed that
extended indolicidins, β-sheet gramicidins, and looped
and linear bactenecins are all quite sensitive to KCl [35].
In this study, the antagonistic effects of KCl was not
observed on MUC7 12-mer, which still showed high anti-
candidal activity in the presence of 40 mM KCl, the con-
centration higher than its physiological concentration in
saliva.
Ca2+ is a major divalent cation in saliva, a potent inhibitor
of histatin 5 candidacidal activity at physiological concen-
trations, and may be the primary ion responsible for the
masking effect of saliva [36]. Our previous study showed
that Ca2+ exhibited inhibitory effect on the fungicidal
activity of MUC7 20-mer (a peptide extended by 8 aa res-
idues at the N-terminus of the MUC7 12-mer) [3]. In this
study, we found that Ca2+ is the only ion that exhibited an
antagonistic effect on MUC7 12-mer against C. albicans.
It has been reported that Mg2+ also inhibits the activity of
antimicrobial peptides, but the inhibition potency is
lower that that of Ca2+. For example, Mg2+ at the physio-
logical concentration (less than 1 mM) does not change
the antibacterial activity of the Sphe-2, a β-defensin from
the king penguin stomach, against S. aureus, and the
growth of E. coli was altered by 2 fold in the presence of 1
mM MgCl2[37]. We have demonstrated (in the previous
study) that more than 5 mM MgCl2 exhibited inhibitory
effect on the candidacidal activity of MUC7 20-mer. The
activity, however, was not altered in the presence of 1 mM
MgCl2 [3]. In this study, we demonstrated that Mg2+,
unlike Ca2+, did not show an antagonistic effect on MUC7
12-mer against C. albicans.
Zn2+ does not exist in saliva, but Zn2+ can enhance the
antimicrobial activity of peptides. It has been reported
that poly(arginyl-histidine) peptide, which shows activity
against a broad range of bacteria and fungi, lost its activity
under conditions of high ionic strength. Zn2+ can specifi-
cally change the circular dichroism spectra of this peptide
and restore its antimicrobial activity under high ionic
strength conditions [38]. Melino et al. reported that Zn2+
ions selectively induce salivary histatin-5 to fuse nega-
tively charged vesicles through a zinc-binding motif
present in its functional domain, and stated that the
action of this antimicrobial peptide is likely mediated by
the presence of zinc ions [39]. Our results are consistent
with the above studies in that Zn2+ exhibits an additive
effect on the antimicrobial activity of MUC7 12-mer.
However, the mechanism of this effect in not known.
Table 3: The normal values of cations and pH in mixed human 
saliva and plasma
Saliva (mM) Plasma (mM)
Ca2+ 1–2 2.5
Mg2+ 0.2–0.5 0.5–1.0
Na+ 6–26 140
K+ 14–32 4
NH4 
+ 1–7 0.03
pH 6.7
pH range 6.2–7.6
Reference: [10]Annals of Clinical Microbiology and Antimicrobials 2007, 6:14 http://www.ann-clinmicrob.com/content/6/1/14
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EDTA (ethylenediamine tetraacetic acid), which chelates
divalent cations, is approved by the FDA as a preservative
in packaged foods, vitamins, and baby food. EDTA has
been widely used in many areas. In medicine, EDTA is
used in chelation therapy for acute hypercalcemia and for
treating mercury or lead poisoning. EDTA is also used as
an anticoagulant for blood samples, and as an anticolla-
genase to prevent the worsening of corneal ulcers in ani-
mals. In dentistry, EDTA is used as a root canal irrigant to
remove organic and inorganic debris (smear layer)
[40,41]. Sen et al. demonstrated that EDTA exhibited the
highest antifungal activity against C. albicans, compared
with those of routine antifungal drugs [42]. Our previous
study showed that that EDTA enhanced the antifungal
activity of MUC7 peptides in human saliva mainly by
chelating the divalent cations (such as Ca+2) [8]. In sup-
port of this discovery, the results of this study indicated
that EDTA has a synergistic effect on the antimicrobial
activity of MUC7 12-mer (Table 1), and abrogates the
activity that was inhibited by Ca2+ (Table 2). These find-
ings suggest that concurrent therapies with EDTA and
MUC7 12-mer may be of value in patients with oral fungal
or bacterial infections, although further studies in vivo are
needed to examine the safety, tolerance, and optimal dos-
ing of EDTA in the treatment of these infections. The
mechanism for the EDTA action is likely that it competes
with microorganism for any of the trace iron and Ca2+
ions that are essential to the maintenance of their life cycle
[43] or it disturbs the integrity of bacterial outer mem-
brane [44]. It may be also due to the fact that EDTA pre-
vents the peptide degradation by the metalloprotease
[45].
In addition to salt sensitivity, antimicrobial peptides are
also pH-dependent. Lee et al. [28] demonstrated that the
activities of histidine-rich, amidated alpha-helical antimi-
crobial peptides were substantially greater at pH 5.5 than
at pH 7.4. In another study, Minahk et al. also showed that
the antilisterial activity of enterocin CRL35 was higher at
acidic than neutral or basic conditions [46]. In contrast,
our study showed that the antimicrobial power of MUC7
12-mer peptide was enhanced in neutral or slightly alkali
media, although the peptide acted in a broad range of pH.
Therefore, saliva with pH range 6.2–7.6 appears to be the
suitable environment for the action of MUC7 12-mer.
Similar observations have been reported for other antimi-
crobial peptides [47,48].
Temperature is also one of the important factors for the
therapeutic application of the peptide. Some antimicro-
bial peptides retained their activity when pre-heated [47].
MUC7 12-mer is also thermo-stable. It retained significant
antimicrobial activity after incubation at 60°C for 30 min.
This thermal stability is probably due to this peptide's very
simple secondary structure that cannot be denatured.
Conclusion
At oral physiological concentrations, the antimicrobial
activity of MUC7 12-mer is not affected by Na+, K+, or
Mg2+, but is inhibited by Ca+2, which has an antagonistic
effect on MUC7 12-mer. However, this inhibition can be
reversed in the presence of EDTA, as EDTA exhibited a
synergistic effect when combined with MUC7 12-mer.
This peptide exerts optimum anticandidal activity at neu-
tral or slightly basic conditions. MUC7 12-mer peptide is
stable, and temperature up to 60°C has not affected its
activity. These findings suggest that MUC7 12-mer pep-
tide, especially in combination with EDTA, could be
potentially applied as an alternative therapeutic agent for
the treatment of human oral candidiasis.
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